MBX Biosciences, Inc. (MBX)

Market Cap	260.71M
Revenue (ttm)	n/a
Net Income (ttm)	-61.92M
Shares Out	33.42M
EPS (ttm)	-5.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,463
Open	8.15
Previous Close	8.13
Day's Range	7.67 - 8.12
52-Week Range	7.65 - 27.50
Beta	n/a
Analysts	Strong Buy
Price Target	37.25 (+377.56%)
Earnings Date	Mar 17, 2025

About MBX

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 cl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 13, 2024
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: MBX
• Website: https://mbxbio.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price forecast is $37.25, which is an increase of 377.56% from the latest price.

Price Target

$37.25

(377.56% upside)

Analyst Consensus: Strong Buy